2022 Rheumatology Year in Review (1-6-2023) Save
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
- FDA Regulatory Approvals & Indications
- Advancing Lupus treatments
- New Guidelines
- Dermatology Drug Hot Spot
- Attack of the Biosimilars
- Multivitamin Letdown
- New PMR/GCA Therapies
- FDA Safety Issues
- Waiting for RA
For more on these topics, read the full article here
Join The Discussion
I am very fortunate to be trained by Dr. Lightfoot. My training would have been never the same without him. He was unarguably the most humble and the most intelligent doctor that I knew.
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.